Immunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristics

BioDrugs

Volumn 27, Issue 1, 2013, Pages 83-84

  Pickett, Andy ^a,b  

^a Toxin Science Limited   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

HEMIDIAPHRAGM; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LETTER; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BOTULINUM TOXINS, TYPE A; CLOSTRIDIUM BOTULINUM; HUMANS;

EID: 84873403450     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-012-0006-1     Document Type: Letter

References (17)

1. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26(2):e1-9.
2. Shone C, Appleton N, Wilton-Smith P, Hambleton P, Modi N, Gatley S, et al. In vitro assays for botulinum toxin and antitoxins. Dev Biol Stand. 1986;64:141-5.
3. Johnson EA, Pellett S, Tepp W, Borodic GE. A neuronal cell-based assay for highly sensitive detection of pharmaceutical preparations of BONT/A and patient neutralizing serum antibodies [abstract]. Toxicon. 2008;51(Suppl. 1):14.
4. Pickett A, Morte C, Pla F, Cedo M, Mirabet M, Peraire C, et al. Development of a multi-step approach for the detection of neutralising antibodies to botulinum toxin Type A [abstract]. Toxicon. 2008;51:18.
5. Schantz EJ, Johnson EA. Dose standardisation of botulinum toxin [letter]. Lancet. 1990;335(8686):421.
6. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56(1):80-99.
7. Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol. 1992;58(10):3426-8.
8. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46(1):26-9.
9. Eisele K-H, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555-65.
10. Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. International conference on basic and therapeutic aspects of botulinum and tetanus toxins; 2002 Jun 8-12; Hannover, R20.
11. Pickett A. Characteristics, properties and applications of botulinum toxins in therapeutic use today in the NHS. Br J Med Procure. 2012;4(1):16-23.
12. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67(5):669-83.
13. Bluemel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type a in the rabbit. International conference on basic and therapeutic aspects of botulinum and tetanus toxins, (Toxins 2005); 2005 Jun 23-25; Denver, CO.
14. Pickett A, Rosales RL. New trends in the science of botulinum toxin-A as applied in dystonia. Int J Neurosci. 2011;121 Suppl. 1(S1):22-34.
15. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32(4):213-8.
16. ®) across multiple indications. Mov Disord. 2010;25(13):2211-8.
17. Bakheit AM, Liptrot A, Newton R, Pickett AM. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res. 2012;35(1):36-9.